News Image

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Provided By PR Newswire

Last update: Nov 14, 2024

— Improved loss from operations by 31% —

— Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections 

Read more at prnewswire.com

ADITXT INC

NASDAQ:ADTX (7/31/2025, 4:30:00 PM)

After market: 1.0701 -0.02 (-1.83%)

1.09

-0.01 (-0.91%)



Find more stocks in the Stock Screener

Follow ChartMill for more